Hemogenyx Pharmaceuticals PLC
HEMO
Company Profile
Business description
Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. The company is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
Contact
6 Heddon Street
LondonW1B 4BT
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
16
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,524.60 | 4.40 | 0.05% |
CAC 40 | 7,836.79 | 37.04 | -0.47% |
DAX 40 | 23,527.01 | 111.55 | -0.47% |
Dow JONES (US) | 42,051.06 | 89.37 | -0.21% |
FTSE 100 | 8,585.01 | 17.91 | -0.21% |
HKSE | 23,565.70 | 74.95 | -0.32% |
NASDAQ | 19,146.81 | 136.72 | 0.72% |
Nikkei 225 | 37,705.74 | 422.39 | -1.11% |
NZX 50 Index | 12,825.62 | 46.36 | 0.36% |
S&P 500 | 5,892.58 | 6.03 | 0.10% |
S&P/ASX 200 | 8,291.50 | 11.90 | 0.14% |
SSE Composite Index | 3,388.61 | 15.34 | -0.45% |